Last Update 17 Apr 26
Fair value Increased 0.76%LH: Expanded Cancer And Alzheimer’s Platforms Will Support Long Term Upside
Analysts have adjusted their price target on Labcorp Holdings slightly higher to $310, citing modest updates to fair value estimates, revenue growth assumptions, future P/E expectations, and a small change in projected profit margins.
What's in the News
- Launched the Labcorp Fentanyl Urine Visual Test, the first FDA cleared rapid fentanyl urine test of its kind manufactured in the US, delivering results in about 10 minutes for use in CLIA certified acute care and clinical settings (Key Developments).
- Introduced an AI powered real world data platform, developed with Amazon Web Services and Datavant, to help researchers and biopharma companies analyze deidentified Alzheimer’s disease data more quickly using large datasets and advanced analytics, with plans to extend into other disease areas in 2026 (Key Developments).
- Announced a collaboration with Children’s Hospital of Philadelphia to create a pediatric diagnostics pipeline aimed at bringing specialized tests for oncology, metabolic disease and autoimmune conditions to children across the US (Key Developments).
- Expanded collaboration with Illumina to advance precision oncology, including potential co commercialization of Labcorp’s FDA authorized PGDx elio plasma focus Dx liquid biopsy assay with Illumina’s FDA approved TruSight Oncology Comprehensive for solid tumor profiling, and continued joint evidence generation in cancer testing (Key Developments).
- Issued full year 2026 revenue guidance of US$14.61b to US$14.79b and reported completion of a share repurchase program totaling 15,259,458 shares, or 17.05% of the company, for US$3,648.85m since December 2021 (Key Developments).
Valuation Changes
- Fair Value: Adjusted slightly higher from $307.71 to $310.06 per share.
- Discount Rate: Held steady at 6.98%, indicating no change in the rate used to discount future cash flows.
- Revenue Growth: Assumption lifted modestly from 4.88% to 4.90%.
- Net Profit Margin: Assumption edged down slightly from 7.62% to 7.61%.
- Future P/E: Target multiple increased slightly from 23.96x to 24.15x.
Key Takeaways
- Strategic collaborations and acquisitions are expected to drive growth in high-growth therapeutic areas and partnerships with health systems.
- Introduction of innovative tests and tech enhancements is anticipated to improve margins and earnings, with initiatives offsetting rising personnel costs.
- Tariffs, regulatory changes, and competitive pressures could negatively affect Labcorp's revenue growth, margins, and earnings amidst global economic shifts and market challenges.
Catalysts
About Labcorp Holdings- Provides laboratory services.
- Labcorp's strategic collaborations and acquisitions, such as with Inspira Health and BioReference Health, are expected to drive revenue growth by expanding its presence in high-growth therapeutic areas like oncology and strengthening partnerships with health systems.
- The introduction of innovative tests in oncology, women's health, autoimmune disease, and neurology is anticipated to capture more test volume and outpace growth in the broader market, positively impacting revenue and earnings.
- The use of AI and technology innovations is enhancing operational efficiencies, improving margins through platforms like eClaim Assist and Labcorp Diagnostic Assistant.
- The Invitae integration is on track to be slightly accretive to earnings for the full year, contributing to overall margin expansion and earnings growth.
- Labcorp's LaunchPad initiative continues to produce expected cost savings, mitigating higher personnel costs and supporting margin expansion.
Labcorp Holdings Future Earnings and Revenue Growth
Assumptions
How have these above catalysts been quantified?
- Analysts are assuming Labcorp Holdings's revenue will grow by 4.9% annually over the next 3 years.
- Analysts assume that profit margins will increase from 6.3% today to 7.6% in 3 years time.
- Analysts expect earnings to reach $1.2 billion (and earnings per share of $17.12) by about April 2029, up from $876.5 million today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $1.4 billion in earnings, and the most bearish expecting $893.1 million.
- In order for the above numbers to justify the price target of the analysts, the company would need to trade at a PE ratio of 24.3x on those 2029 earnings, down from 25.4x today. This future PE is greater than the current PE for the US Healthcare industry at 23.0x.
- Analysts expect the number of shares outstanding to decline by 1.55% per year for the next 3 years.
- To value all of this in today's terms, we will use a discount rate of 6.98%, as per the Simply Wall St company report.
Risks
What could happen that would invalidate this narrative?- The impact of tariffs and regulatory changes could create cost pressures, affecting Labcorp Holdings' overall revenue growth and net margins, as they must either absorb costs or pass them on to customers.
- Ongoing shifts in the macroeconomic landscape, such as foreign exchange volatility and global economic conditions, could adversely impact Labcorp's revenue and earnings projections.
- The potential financial implications of PAMA (Protecting Access to Medicare Act) could lead to a $100 million impact on revenue, affecting net earnings if the legislation goes into effect without a delay or amendment.
- Competitive pressures in the Diagnostic Laboratories sector may affect pricing and margins, impacting Labcorp's revenue and net margins as contracts come up for renewal or new competitive bids are issued.
- The unpredictability and possible delays in clinical trial starts, due to regulatory review processes and biopharma R&D funding, could impact the Biopharma Laboratory Services segment's revenue and earnings.
Valuation
How have all the factors above been brought together to estimate a fair value?
- The analysts have a consensus price target of $310.06 for Labcorp Holdings based on their expectations of its future earnings growth, profit margins and other risk factors.
- However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $347.0, and the most bearish reporting a price target of just $270.0.
- In order for you to agree with the analysts, you'd need to believe that by 2029, revenues will be $16.1 billion, earnings will come to $1.2 billion, and it would be trading on a PE ratio of 24.3x, assuming you use a discount rate of 7.0%.
- Given the current share price of $270.68, the analyst price target of $310.06 is 12.7% higher.
- We always encourage you to reach your own conclusions though. So sense check these analyst numbers against your own assumptions and expectations based on your understanding of the business and what you believe is probable.
Have other thoughts on Labcorp Holdings?
Create your own narrative on this stock, and estimate its Fair Value using our Valuator tool.
Create NarrativeHow well do narratives help inform your perspective?
Disclaimer
AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.